What the FDA decided on Joenja for Activated PI3K Delta Syndrome
The FDA approved Joenja (leniolisib) for activated PI3K delta syndrome (APDS), children 4 to 11.
Approved September 11, 2026 as the first treatment for APDS in children aged 4 to 11 who weigh at least 27kg (about 60 pounds), with weight-based dosing. Joenja was first approved in 2023 for ages 12 and up. The FDA based the pediatric approval on safety and drug-level data from a single-arm, open-label study in which 8 children received the recommended weight-based dose.
Who the Joenja decision matters to
Activated PI3K delta syndrome (APDS) is a rare inherited immune disorder in which an overactive enzyme keeps immune cells from working properly, causing repeated sinus and lung infections, swollen lymph nodes and a higher risk of lymphoma.
Prevalence: About 1 to 2 people per million worldwide (Pharming, citing a 2023 estimate); MedlinePlus Genetics notes the exact number is unknown. See our full Activated PI3K Delta Syndrome page for current treatments, recruiting trials, and community resources.
How Joenja works
Joenja: oral inhibitor of PI3K-delta, the immune cell enzyme that is overactive in activated PI3K delta syndrome. Our full Joenja profile covers how it works, side effects in plain language, and its trial history.
Where Activated PI3K Delta Syndrome treatment stands today
Read our full Activated PI3K Delta Syndrome treatment summary
Few APDS trials are open. As of October 2026, ClinicalTrials.gov lists no recruiting treatment trials for APDS. Pharming's Joenja studies in children aged 4 to 11 (NCT05438407) and 1 to 6 (NCT05693129) are active but no longer recruiting.
A separate biomarker study (NCT06694363) is recruiting. The FDA is reviewing lower Joenja doses for children 4 to 11 who weigh 13 to 27kg, with a decision due January 30, 2027.
Trials and Joenja both need a confirmed PIK3CD or PIK3R1 variant, so genetic testing is the first step if APDS is suspected. The Immune Deficiency Foundation can help find an immunologist experienced with APDS.
The Activated PI3K Delta Syndrome page has every treatment and trial →You'll hear about future FDA decisions and new recruiting trials for Activated PI3K Delta Syndrome. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
Has the FDA decided on Joenja?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: FDA approval notice
What was Joenja approved for?
The FDA approved Pharming's sNDA for Joenja in Activated PI3K delta syndrome (APDS), children 4 to 11.
What to know: Approved September 11, 2026 as the first treatment for APDS in children aged 4 to 11 who weigh at least 27kg (about 60 pounds), with weight-based dosing. Joenja was first approved in 2023 for ages 12 and up. The FDA based the pediatric approval on safety and drug-level data from a single-arm, open-label study in which 8 children received the recommended weight-based dose.
How it works: Oral inhibitor of PI3K-delta, the immune cell enzyme that is overactive in activated PI3K delta syndrome.
More: the Joenja drug page explains it in plain language.
Is there already an FDA-approved treatment for Activated PI3K Delta Syndrome?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Activated PI3K Delta Syndrome.
Approved: Joenja (leniolisib).
Check: the Activated PI3K Delta Syndrome page also searches FDA drug labels for approved treatments.
What did the Joenja trials show?
In a 12-week randomized, placebo-controlled trial (NCT02435173) of 31 people 12 and older (21 on Joenja, 10 on placebo), the size of the largest lymph nodes shrank more on Joenja (a log-scale change of 0.27 against 0.02), and naive B cells rose 37.4 percentage points against 0.1. The pediatric approval rests on a study of 8 children aged 4 to 11 (NCT05438407) that looked at safety and drug levels.
More: the Joenja drug page has the full trial history and sources.
What are the side effects of Joenja?
Joenja has no boxed warning. It may harm an unborn baby, so a pregnancy check is done before starting and effective birth control is used until 1 week after the last dose.
Most common: Headache (24% against 20% on placebo), Sinusitis (19% against 0%), Eczema (14% against 0%), Fast heartbeat (10% against 0%), Diarrhea, fever, back pain, neck pain and hair loss (10% each against 0%), In children 4 to 11: belly pain, cough and respiratory infection.
More: the Joenja drug page has the label's warnings in full.
How much will Joenja cost?
Trial Friend does not list a price for Joenja. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Joenja decision?
The FDA approved Joenja for Activated PI3K delta syndrome (APDS), children 4 to 11 on September 11, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from FDA approval notice. This page rechecks against our calendar, which is re-verified daily.